Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of inotuzumab ozogamicin versus ALLR3 induction in children with first high-risk relapsed B-cell precursor acute lymphoblastic leukemia
MOH_2023-01-25_012311Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Pfizer. Primary endpoint: MRD-negative complete remission rate after one induction cycle. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2023-01-25_012311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-25_012311.